Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

First Wave Biopharma Inc (NQ: FWBI )

3.020 -0.100 (-3.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about First Wave Biopharma Inc

Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI
Via AB Newswire
First Wave BioPharma (NASDAQ: FWBI) Makes Significant Progress in Phase 2 SPAN Clinical Trial
Trial Enrollment Completed for Investigational Therapy of Exocrine Pancreatic Insufficiency First Wave BioPharma, Inc. (NASDAQ: FWBI), a clinical-stage biopharmaceutical company 
Via Spotlight Growth
HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors
From HOOKIPA Pharma Inc.
Via GlobeNewswire
First Wave BioPharma, Inc. (NASDAQ: FWBI) Featured in Coverage of the 35th Annual Roth Conference
Via Investor Brand Network
First Wave BioPharma Files IND For Enhanced Formulation Of Adrulipase; Topline Results Expected 1H/2023 ($FWBI)
Via AB Newswire
First Wave BioPharma’s Reformulated Adrulipase Targets Front Line Position Treating Certain Exocrine Pancreatic Insufficiency ($FWBI)
Via AB Newswire
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews James Sapirstein CEO, First Wave BioPharma, Inc.
Via ACCESSWIRE
First Wave BioPharma Stock Bid Higher After Adrulipase Study Update; Expects To File IND Application In Q4 ($FWBI)
Via AB Newswire
Exposures Product Safety
First Wave BioPharma Earns $16 PT From Goldman SCR; Expects 1691% Surge As 2021 Milestones Become 2022 Catalysts ($FWBI)
Via AB Newswire
Exposures COVID-19
First Wave BioPharma, Inc. (NASDAQ: FWBI) Featured in Virtual Coverage of the 34th Annual Roth Conference
Via Investor Brand Network
Exposures COVID-19
First Wave BioPharma’s Fast-Tracked Phase 2 Candidate To Treat COVID-RELATED GI Tract Infection Gives Hope To Millions (NASDAQ: FWBI)
Via AB Newswire
First Wave BioPharma On Track For Transformational 2022, EUA And Phase-2 COVID-Related GI Trial Data In Focus (NASDAQ: FWBI)
Via AB Newswire
With Full Enrollment Complete In Its Phase 2 COVID-Related GI Treatment Trial, First Wave Bio Could Earn An EUA Sooner Than Later (NASDAQ: FWBI)
Via AB Newswire
A Deeper Dive Into AzurRx BioPharma’s Acquisition Of First Wave Bio; Low Up-Front Terms Are Very Shareholder Friendly (NASDAQ: FWBI)
Via AB Newswire
First Wave BioPharma Initiates Phase2b Trial Targeting Unmet Treatment For Ulcerative Proctitis And UPS; Adds To Growing List Of 2021 Milestones (NASDAQ: FWBI)
Via AB Newswire
First Wave BioPharma Launched: AzurRx BioPharma and First Wave Bio Merge To Target Billion Dollar GI and IBD Treatment Markets (NASDAQ: FWBI)
Via AB Newswire
First Wave Bio And AzrurRx BioPharma Combine To Target Billion Dollar GI and IBD Treatment Market; Completes Massive $229 Million Deal (NASDAQ: FWBI)
Via AB Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.